Clearmind Medicine (CMND)
Market Price (7/16/2026): $1.86 | Market Cap: $0.6 MilSector: Health Care | Industry: Biotechnology
Clearmind Medicine (CMND)
Market Price (7/16/2026): $1.86Market Cap: $0.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -2458% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Psychedelic Therapeutics. | Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -172% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.1 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1442% High stock price volatilityVol 12M is 161% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 67% Key risksCMND key risks include [1] a precarious financial position with zero revenue and significant ongoing losses, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -2458% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Psychedelic Therapeutics. |
| Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -172% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.1 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1442% |
| High stock price volatilityVol 12M is 161% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 67% |
| Key risksCMND key risks include [1] a precarious financial position with zero revenue and significant ongoing losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Clearmind Medicine (CMND) stock has lost about 85% since 3/31/2026 because of the following key factors:
1. Substantial Share Dilution. Clearmind Medicine has experienced significant share dilution over the past year, with total shares outstanding increasing by 11473.3%. This substantial increase in the number of shares reduces the value of existing holdings, contributing to the downward pressure on the stock price since fiscal Q2 2026 (which ended April 30, 2026) and into the current period.
2. Continued Negative Financial Performance and Cash Burn. The company reported a net loss of -$2.0 million for fiscal Q2 2026, which ended on April 30, 2026. For the trailing 12 months ending on the same date, Clearmind Medicine's total earnings were -$7.9 million. Additionally, the company utilized $3.9 million in cash for operating activities during the six months ending April 30, 2026, indicating ongoing operational losses and a consistent need for funding.
Show more
Clearmind Medicine (CMND) stock has lost about 85% since 3/31/2026 because of the following key factors:
1. Substantial Share Dilution. Clearmind Medicine has experienced significant share dilution over the past year, with total shares outstanding increasing by 11473.3%. This substantial increase in the number of shares reduces the value of existing holdings, contributing to the downward pressure on the stock price since fiscal Q2 2026 (which ended April 30, 2026) and into the current period.
2. Continued Negative Financial Performance and Cash Burn. The company reported a net loss of -$2.0 million for fiscal Q2 2026, which ended on April 30, 2026. For the trailing 12 months ending on the same date, Clearmind Medicine's total earnings were -$7.9 million. Additionally, the company utilized $3.9 million in cash for operating activities during the six months ending April 30, 2026, indicating ongoing operational losses and a consistent need for funding.
3. Inherent Volatility and Negative Market Reactions Despite Clinical Progress. As a clinical-stage biotechnology company, Clearmind Medicine's stock is characterized by extreme volatility and is highly sensitive to market sentiment regarding its clinical trials and future prospects. Despite announcing positive clinical milestones, such as completing dosing for all participants in Part A of its FDA-regulated Phase I/II clinical trial for CMND-100 by mid-June 2026 and reporting a strong safety profile, the stock has experienced sharp declines. For instance, on June 22, 2026, the stock declined by 4.56% following the announcement of successfully completing treatment for all participants in Part A of the CMND-100 trial, indicating investor skepticism or profit-taking despite seemingly favorable news. The stock has shown dramatic swings, including a "sharp reset" in mid-May 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
The -82.5% change in CMND stock from 3/31/2026 to 7/15/2026 was primarily driven by a -61.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312026 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.40 | 1.82 | -82.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -61.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 7/15/2026| Return | Correlation | |
|---|---|---|
| CMND | -82.5% | |
| Market (SPY) | 16.1% | -8.5% |
| Sector (XLV) | 8.0% | -11.3% |
Fundamental Drivers
The -89.9% change in CMND stock from 12/31/2025 to 7/15/2026 was primarily driven by a -95.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.10 | 1.82 | -89.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -95.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 7/15/2026| Return | Correlation | |
|---|---|---|
| CMND | -89.9% | |
| Market (SPY) | 11.0% | -2.8% |
| Sector (XLV) | 2.7% | -6.2% |
Fundamental Drivers
The -99.5% change in CMND stock from 6/30/2025 to 7/15/2026 was primarily driven by a -95.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 360.00 | 1.82 | -99.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -95.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 7/15/2026| Return | Correlation | |
|---|---|---|
| CMND | -99.5% | |
| Market (SPY) | 23.2% | 1.3% |
| Sector (XLV) | 19.0% | -11.5% |
Fundamental Drivers
The -100.0% change in CMND stock from 6/30/2023 to 7/15/2026 was primarily driven by a -99.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302023 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 5700.00 | 1.82 | -100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -99.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2023 to 7/15/2026| Return | Correlation | |
|---|---|---|
| CMND | -100.0% | |
| Market (SPY) | 76.3% | 4.6% |
| Sector (XLV) | 24.9% | -3.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CMND Return | - | -46% | -97% | -51% | -97% | -89% | -100% |
| Peers Return | -61% | -44% | -24% | -42% | 216% | 18% | -64% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| CMND Win Rate | - | 0% | 17% | 42% | 17% | 14% | |
| Peers Win Rate | 36% | 43% | 42% | 38% | 58% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| CMND Max Drawdown | - | - | -98% | -66% | -97% | -93% | |
| Peers Max Drawdown | -77% | -81% | -62% | -73% | -61% | -37% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ATAI, AXSM, RLMD, NRXP, ENVB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/15/2026 (YTD)
How Low Can It Go
| Event | CMND | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -27.6% | -7.8% |
| % Gain to Breakeven | 38.1% | 8.5% |
| Time to Breakeven | 64 days | 18 days |
In The Past
Clearmind Medicine's stock fell -27.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 38.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CMND | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -27.6% | -7.8% |
| % Gain to Breakeven | 38.1% | 8.5% |
| Time to Breakeven | 64 days | 18 days |
In The Past
Clearmind Medicine's stock fell -27.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 38.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Clearmind Medicine (CMND)
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical company focused on the discovery and development of novel therapeutics derived from psychedelic compounds. The company's primary objective is to address significant unmet medical needs within the mental health and addiction sectors, leveraging the potential of these unique substances to create innovative treatment solutions.
The core of Clearmind Medicine's product pipeline is centered on MEAI (5-methoxy-2-aminoindane), a proprietary and novel psychoactive substance. Their lead product candidate, CMND-100, which incorporates MEAI, is currently under development for the treatment of alcohol use disorder (AUD). Beyond AUD, the company is actively exploring the therapeutic applications of MEAI and other compounds for a range of conditions, including various eating disorders, depression, and obesity, as part of its strategy to build a robust intellectual property portfolio.
Clearmind Medicine operates within the global pharmaceutical market, specifically targeting the mental health, addiction treatment, and neurological disorder segments. As a clinical-stage company, its ultimate market objective is to provide safe and effective treatment options to patients worldwide who suffer from these debilitating conditions, aiming to improve patient outcomes where current therapeutic approaches may be insufficient.
```AI Analysis | Feedback
Here are 1-3 brief analogies for Clearmind Medicine (CMND):
- MindMed or Compass Pathways, but specializing in non-hallucinogenic psychedelic-derived medicines.
- An early-stage pharmaceutical company, but focused entirely on developing therapeutic drugs from psychedelic compounds.
AI Analysis | Feedback
- CMND-100 (MEAI) for Alcohol Use Disorder (AUD): A proprietary psychedelic-derived compound in clinical development for treating alcohol use disorder.
- CMND-100 (MEAI) for Binge Eating Disorder (BED): A proprietary psychedelic-derived compound in clinical development for treating binge eating disorder.
AI Analysis | Feedback
Clearmind Medicine (CMND) is a pharmaceutical company primarily engaged in the research and development of psychedelic-derived therapeutics for various neurological and psychiatric indications. As the company is currently in the pre-clinical and clinical trial stages, it does not yet have commercialized products. Therefore, Clearmind Medicine does not currently have major customers in the traditional sense of selling products or services to other companies or individuals.
Its business model at this stage is focused on advancing its drug candidates through the regulatory approval process, rather than generating revenue from product sales.
```AI Analysis | Feedback
AI Analysis | Feedback
Adi Zuloff-Shani, PhD Chief Executive Officer
Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with over 20 years of strategic and operational leadership experience in the healthcare industry. Her expertise includes a deep understanding of therapeutics development in heavily regulated environments. She was appointed CEO in July 2021.
Alan Rootenberg Chief Financial Officer
Alan Rootenberg is a chartered professional accountant with extensive experience serving as the Chief Financial Officer for a number of publicly traded companies listed on the TSX, TSXV, CSE, and OTCBB. His background encompasses roles in mineral exploration, mining, technology, and medical cannabis companies.
Mary-Elizabeth Gifford Chief of Global Impact
Mary-Elizabeth Gifford focuses on building bridges between research, regulation, and patient care to accelerate the development of responsible regulated psychedelic medicines. Before joining Clearmind, she served as Chief of Global Impact at Psyence BioMed, a Nasdaq-listed biopharmaceutical company, and previously led public policy at the Center for Mind-Body Medicine, a non-profit organization. She is educated at Brown University and pursued postgraduate studies at Harvard.
Mark Haden, MSW VP Business Development
Mark Haden holds an MSW and is responsible for business development at Clearmind Medicine.
Gadi Levin, MBA VP Finance
Gadi Levin holds an MBA and serves as the Vice President of Finance.
AI Analysis | Feedback
The key risks to Clearmind Medicine (CMND) are:
-
Going Concern and Financial Health: Clearmind Medicine faces substantial doubt regarding its ability to continue as a going concern. The company has reported negative operating cash flows, an accumulated deficit, and is heavily reliant on securing additional financing to fund its operations and ongoing clinical trials. It currently generates no revenue and has significant losses.
-
Drug Development and Regulatory Risks: As a clinical-stage biotechnology company, Clearmind Medicine is exposed to the inherent uncertainties of drug development. The success of its pipeline, including CMND-100 for Alcohol Use Disorder, depends on navigating lengthy and costly clinical trials, and ultimately, obtaining regulatory approvals, which are not guaranteed.
-
Shareholder Dilution and Stock Volatility: Shareholders have experienced substantial dilution in the past year, a common occurrence for early-stage biotech companies that frequently need to raise capital. Additionally, the stock exhibits high volatility, leading to significant price fluctuations.
AI Analysis | Feedback
AI Analysis | Feedback
Clearmind Medicine (CMND) focuses on developing novel psychedelic-derived therapeutics for various underserved health problems. The addressable markets for their main products and services are as follows:
-
Alcohol Use Disorder (AUD): The global alcohol addiction market is projected to reach approximately US$6.2 billion by 2033. In the United States, the Alcohol Use Disorder market size was approximately USD 1.106 billion in 2025 and is projected to increase to USD 3.489 billion by 2034. North America is expected to be the leading region in the global alcohol addiction market, holding around a 45% share.
-
Obesity and Metabolic Syndrome: The global obesity management market was valued at $140.3 billion in 2023 and is projected to reach $351.8 billion by 2033. In the seven major markets (France, Germany, Italy, Japan, Spain, the UK, and the US), the obesity market is estimated to exceed $173.5 billion by 2031. The United States alone accounted for over $2 billion of the obesity market size in 2023.
-
Eating Disorders (including Anorexia Nervosa and Binge Eating Disorder): The global Appetite (Eating) Disorders Market is forecast to reach $800 million by 2030. For Anorexia Nervosa specifically, the total treatment market size in the 7MM (United States, EU4, UK, and Japan) was approximately USD 60 million in 2023, with the US contributing about USD 30 million. The binge-eating disorder treatment market size is forecast to increase by USD 627.4 million between 2024 and 2029. North America generally dominates the eating disorder market.
-
Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), and Anxiety Disorders (within the psychedelic therapeutics context): The global psychedelic therapeutics market size was estimated at USD 2.94 billion in 2025 and is predicted to increase to approximately USD 11.03 billion by 2034. Another estimate for the global psychedelic drugs market size was USD 1.82 billion in 2025, projected to grow to USD 5.16 billion by 2034. The Major Depressive Disorder market itself is projected to be above $25 billion by 2030. North America held approximately 38% of the global psychedelic drugs market size in 2023 and is expected to remain a strong market.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Clearmind Medicine (CMND) over the next 2-3 years:
- Advancement and Commercialization of CMND-100 for Alcohol Use Disorder (AUD): Clearmind Medicine's lead drug candidate, CMND-100, is a proprietary non-hallucinogenic oral compound based on MEAI, currently in FDA-approved Phase I/IIa clinical trials for Alcohol Use Disorder (AUD). The company recently advanced enrollment for the third cohort in this trial, following positive safety and tolerability results from the second cohort, and received approval from the Data and Safety Monitoring Board to continue. Successful progression through clinical trials, regulatory approval, and subsequent market launch would be a primary driver of future revenue.
- Development and Commercialization of MEAI for Obesity and Metabolic Disorders: Clearmind Medicine is actively developing its MEAI compound for the treatment of obesity and metabolic disorders, including a potential alcohol substitute consumer product. Preclinical studies have demonstrated promising results, such as approximately 20% weight reduction in diet-induced obese mice. The company has filed patents in this area and is collaborating with partners like NeuroThera Labs and Polyrizon Ltd. to develop an intranasal MEAI formulation for enhanced delivery. The successful development and commercialization of these products would contribute significantly to future revenue.
- Expansion of the Pipeline and Intellectual Property for Additional Mental Health Conditions: Clearmind Medicine has a broad focus on addressing various underserved mental health problems, including binge drinking, eating disorders, anxiety disorders, post-traumatic stress disorder (PTSD), and depression. The company maintains a robust intellectual property portfolio with 19 patent families and 31 granted patents. The continued research, development, and eventual commercialization of novel psychedelic-derived therapeutics for these indications, potentially through collaborations such as with Yissum Research Development Company for PTSD, represent additional avenues for revenue generation.
- Strategic Collaborations and Partnerships: The company has established several key collaborations, including with SciSparc Ltd. for combination treatment for obesity and metabolic syndrome, Yissum Research Development Company for PTSD and other conditions, Polyrizon Ltd. for an intranasal MEAI formulation, and NeuroThera Labs for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. Successful execution and expansion of these partnerships, potentially leading to co-development agreements, licensing deals, or shared commercialization efforts, could provide substantial revenue streams for Clearmind Medicine.
AI Analysis | Feedback
Share Issuance
- The number of shares outstanding for Clearmind Medicine increased by 305.49% in one year.
- In November 2025, Clearmind Medicine priced a registered direct offering of common shares and pre-funded warrants, expecting to raise approximately $0.788 million in gross proceeds.
- Equity issuances, warrant exercises, and the conversion of convertible loans into shares contributed to an increase in cash and cash equivalents to $9.26 million and working capital to $8.12 million as of January 31, 2026, while also reducing total liabilities.
Inbound Investments
- As of January 31, 2026, the company's cash and cash equivalents increased to $9.26 million and working capital to $8.12 million, driven by equity issuances, warrant exercises, and the conversion of convertible loans into shares, which also reduced total liabilities to $2.91 million.
Capital Expenditures
- Clearmind Medicine's financial data as of January 31, 2026, indicates that operating expenses rose, mainly due to higher general and administrative and research and development costs.
- Capital expenditure figures for CMND are not available in recent financial summaries.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.91 |
| Mkt Cap | 0.3 |
| Rev LTM | 1 |
| Op Inc LTM | -39 |
| FCF LTM | -29 |
| FCF 3Y Avg | -32 |
| CFO LTM | -29 |
| CFO 3Y Avg | -32 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 75.6% |
| Rev Chg 3Y Avg | 145.4% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 10.9% |
| Op Inc Chg LTM | 3.3% |
| Op Inc Chg 3Y Avg | 12.2% |
| Op Mgn LTM | -746.9% |
| Op Mgn 3Y Avg | -8,341.1% |
| QoQ Delta Op Mgn LTM | 1.6% |
| CFO/Rev LTM | -651.0% |
| CFO/Rev 3Y Avg | -6,369.5% |
| FCF/Rev LTM | -651.0% |
| FCF/Rev 3Y Avg | -6,453.4% |
Price Behavior
| Market Price | $1.82 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/15/2022 | |
| Distance from 52W High | -99.6% | |
| 50 Days | 200 Days | |
| DMA Price | $3.30 | $76.51 |
| DMA Trend | down | down |
| Distance from DMA | -44.9% | -97.6% |
| 3M | 1YR | |
| Volatility | 226.1% | 161.8% |
| Downside Capture | 561.28 | 443.62 |
| Upside Capture | -153.54 | -282.85 |
| Correlation (SPY) | -9.0% | -0.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -3.37 | -1.44 | -1.12 | -0.38 | 0.17 | 0.41 |
| Up Beta | 4.65 | 0.18 | -0.71 | -2.16 | 0.51 | 0.01 |
| Down Beta | -14.65 | -12.52 | -7.23 | -3.60 | -2.22 | -0.27 |
| Up Capture | -361% | -140% | -143% | -64% | -65% | -6% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 3 | 10 | 22 | 47 | 95 | 290 |
| Down Capture | 115% | 506% | 411% | 259% | 199% | 113% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 15 | 28 | 37 | 73 | 147 | 419 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CMND | |
|---|---|---|---|---|
| CMND | -99.5% | 161.5% | -2.51 | - |
| Sector ETF (XLV) | 18.8% | 15.8% | 0.90 | -11.9% |
| Equity (SPY) | 21.9% | 12.6% | 1.30 | 0.2% |
| Gold (GLD) | 21.0% | 27.9% | 0.67 | 6.4% |
| Commodities (DBC) | 29.1% | 18.9% | 1.22 | 0.1% |
| Real Estate (VNQ) | 12.6% | 13.9% | 0.61 | -3.0% |
| Bitcoin (BTCUSD) | -46.2% | 42.9% | -1.32 | 10.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CMND | |
|---|---|---|---|---|
| CMND | -87.9% | 138.6% | -1.38 | - |
| Sector ETF (XLV) | 5.8% | 14.9% | 0.21 | -4.2% |
| Equity (SPY) | 13.2% | 17.1% | 0.59 | 2.3% |
| Gold (GLD) | 17.2% | 18.4% | 0.76 | 2.4% |
| Commodities (DBC) | 9.0% | 19.5% | 0.35 | -2.5% |
| Real Estate (VNQ) | 2.7% | 18.9% | 0.04 | 5.3% |
| Bitcoin (BTCUSD) | 13.8% | 53.5% | 0.44 | 7.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CMND | |
|---|---|---|---|---|
| CMND | -65.3% | 138.6% | -1.38 | - |
| Sector ETF (XLV) | 10.0% | 16.6% | 0.49 | -4.2% |
| Equity (SPY) | 15.6% | 17.9% | 0.74 | 2.3% |
| Gold (GLD) | 11.1% | 16.1% | 0.56 | 2.4% |
| Commodities (DBC) | 6.7% | 18.0% | 0.29 | -2.5% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 5.3% |
| Bitcoin (BTCUSD) | 57.9% | 66.2% | 0.98 | 7.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/15/2026 | 6-K |
| 01/31/2026 | 03/12/2026 | 6-K |
| 10/31/2025 | 01/20/2026 | 20-F |
| 07/31/2025 | 09/11/2025 | 6-K |
| 04/30/2025 | 06/12/2025 | 6-K |
| 01/31/2025 | 03/13/2025 | 6-K |
| 10/31/2024 | 01/22/2025 | 20-F |
| 07/31/2024 | 09/16/2024 | 6-K |
| 04/30/2024 | 06/13/2024 | 6-K |
| 01/31/2024 | 03/19/2024 | 6-K |
| 10/31/2023 | 01/29/2024 | 20-F |
| 07/31/2023 | 09/13/2023 | 6-K |
| 04/30/2023 | 06/14/2023 | 6-K |
| 01/31/2023 | 03/17/2023 | 6-K |
| 10/31/2022 | 02/06/2023 | 20-F |
| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/15/2026 | 6-K |
| 01/31/2026 | 03/12/2026 | 6-K |
| 10/31/2025 | 01/20/2026 | 20-F |
| 07/31/2025 | 09/11/2025 | 6-K |
| 04/30/2025 | 06/12/2025 | 6-K |
| 01/31/2025 | 03/13/2025 | 6-K |
| 10/31/2024 | 01/22/2025 | 20-F |
| 07/31/2024 | 09/16/2024 | 6-K |
| 04/30/2024 | 06/13/2024 | 6-K |
| 01/31/2024 | 03/19/2024 | 6-K |
| 10/31/2023 | 01/29/2024 | 20-F |
| 07/31/2023 | 09/13/2023 | 6-K |
| 04/30/2023 | 06/14/2023 | 6-K |
| 01/31/2023 | 03/17/2023 | 6-K |
| 10/31/2022 | 02/06/2023 | 20-F |
Insider Activity
Updated 6/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hrt, Financial LP | Direct | Sell | 6182026 | 3.31 | 22,139 | 73,192 | 268,953 | Form | |
| 2 | Hrt, Financial LP | Direct | Sell | 6172026 | 3.32 | 3,183 | 10,568 | 343,593 | Form | |
| 3 | Hrt, Financial LP | Direct | Sell | 6162026 | 3.36 | 2,102 | 7,063 | 358,428 | Form | |
| 4 | Hrt, Financial LP | Direct | Sell | 6122026 | 0.12 | 225,191 | 27,698 | 226,083 | Form | |
| 5 | Hrt, Financial LP | Direct | Buy | 6122026 | 0.15 | 2,159,052 | 330,335 | 315,680 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hrt, Financial LP | Direct | Sell | 6182026 | 3.31 | 22,139 | 73,192 | 268,953 | Form | |
| 2 | Hrt, Financial LP | Direct | Sell | 6172026 | 3.32 | 3,183 | 10,568 | 343,593 | Form | |
| 3 | Hrt, Financial LP | Direct | Sell | 6162026 | 3.36 | 2,102 | 7,063 | 358,428 | Form | |
| 4 | Hrt, Financial LP | Direct | Sell | 6122026 | 0.12 | 225,191 | 27,698 | 226,083 | Form | |
| 5 | Hrt, Financial LP | Direct | Buy | 6122026 | 0.15 | 2,159,052 | 330,335 | 315,680 | Form |
Clearmind Medicine — Investor Video Playlist
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.